alpha-aminopyridine has been researched along with Leukocytopenia in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arteaga, CL; Beck, JT; Cameron, DA; Conte, P; Germa, C; Hart, LL; Hortobagyi, GN; Jakobsen, E; Lindquist, D; Mondal, S; O'Shaughnessy, J; Petrakova, K; Sonke, GS; Souami, F; Villanueva, C | 1 |
Dong, M; Fan, Y; Feng, J; Hong, X; Huang, H; Ke, X; Li, W; Lu, X; Ning, Z; Qi, J; Shen, Z; Shi, Y; Yu, L; Zhang, W; Zhao, X; Zhou, D; Zhu, J | 1 |
Carlson, C; Ivanova, A; McRee, AJ; O'Neil, BH; Sanoff, HK | 1 |
3 trial(s) available for alpha-aminopyridine and Leukocytopenia
Article | Year |
---|---|
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Chemotherapy-Induced Febrile Neutropenia; Female; Humans; Incidence; Kaplan-Meier Estimate; Letrozole; Leukopenia; Middle Aged; Postmenopause; Progression-Free Survival; Purines; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Time Factors | 2018 |
Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Benzamides; Disease-Free Survival; Enteropathy-Associated T-Cell Lymphoma; Female; Histone Deacetylase Inhibitors; Humans; Leukopenia; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Mycosis Fungoides; Neoplasm Recurrence, Local; Neutropenia; Skin Neoplasms; Thrombocytopenia; Treatment Outcome; Young Adult | 2015 |
A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors.
Topics: Administration, Oral; Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Fluorouracil; Humans; Leucovorin; Leukopenia; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Organoplatinum Compounds; Phosphoinositide-3 Kinase Inhibitors | 2015 |